You are here

Approvals, Launches, and New Indications

Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Fast-acting insulin aspart may simplify mealtime dosing
No more worry about ineffective cleaning
Company says it is offering a more affordable generic to the agent used to treat varicose veins
New model uses piezoelectric material used in microphones and high-end speakers
New Novartis drug cuts rate of crises by 45% relative to placebo
New drug addresses bacterial resistance to standard therapy
Ziextenzo helps lower the incidence of febrile neutropenia
Drug resistance in HIV patients has nearly tripled since 2001
Drug resistance in HIV patients has nearly tripled since 2001
Scenesse is new treatment for people with rare, painful light sensitivity disease
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
First Oral Formulation in the GLP-1 Class
U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
Studies Show Reduced Symptoms, Clinical Remission
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
100% of Responders Maintained Response for 12 Months or More
Showed Significant Improvement in Metastasis-Free Survival
May Be Used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Polyangiitis
Otezla Approved for Behçet’s Syndrome
For Diabetic Neuropathic Pain, Fibromyalgia, Partial-Onset Seizures, and More
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases